Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.75 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.58 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.58 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.58 |
| ▸ | LDHA | P00338 | 1/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | FBP1 | P09467 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.58 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.58 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.58 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.58 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.58 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.58 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15329077 | 1.00 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30583012 | 0.92 | ADORA1 (0.62) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL15329251 | 0.92 | ADORA1 (0.62) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL2217172 | 0.92 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL888085 | 0.92 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29384615 | 0.92 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8325770 | 0.91 | ADORA1 (0.85) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30670292 | 0.90 | ADORA1 (0.76) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL17438017 | 0.90 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL24264106 | 0.89 | ADORA1 (0.61) | ADORA1DNPH1PRKAB2TRPM2LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | claimed |
| US-12553050-B2 | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-02-17 | — | — | US | disclosed |
| US-20250297260-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CYTOCHROME P450 FAMILY 7 SUBFAMILY A MEMBER 1 (CYP7A1) EXPRESSION | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-25 | — | — | US | disclosed |
| EP-4594491-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | Contera Pharma A/S (DK) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025068557-A1 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2025-04-03 | — | — | WO | disclosed |
| CN-119662650-A | RNAi agents for inhibiting alpha-ENaC expression and methods of use | 箭头药业股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-110832077-B | RNAi agents for inhibiting alpha-ENaC expression and methods of use | 箭头药业股份有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118879696-A | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC 3) | 箭头药业股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-111107853-B | RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC 3) | 箭头药业股份有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2024068997-A2 | ANTISENSE OLIGONUCLEOTIDES FOR THE TREATMENT OF CANAVAN DISEASE | CONTERA PHARMA A/S (DK) | 2024-04-04 | — | — | WO | disclosed |
| CN-117701562-A | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL 3) and methods of use | 箭头药业股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-111343994-B | RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL 3) and methods of use | 箭头药业股份有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12553050-B2 | Compositions and methods for inhibiting cytochrome P450 family 7 subfamily a member 1 (CYP7A1) expression | CYP7A1, CYP7B1, CYP27A1 | ADORA1 804/4885DNPH1 4130/4885PRKAB2 3204/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | ADORA1 4464/4885DNPH1 3616/4885PRKAB2 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.